Phase 2 Study of Sorafenib in the Management of Liver Function Impaired Advanced Hepatocellular Carcinoma
Phase of Trial: Phase II/III
Latest Information Update: 15 Feb 2018
Price : $35 *
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 13 Feb 2018 Status changed from recruiting to completed.
- 13 Oct 2015 Planned end date changed from 1 Jul 2014 to 1 Jul 2016, as reported by ClinicalTrials.gov.
- 13 Oct 2015 Planned primary completion date changed from 1 Jan 2014 to 1 Jan 2016, as reported by ClinicalTrials.gov.